Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib vs placebo in radioiodine-refractory differentiated thyroid cancer
CTR20160121Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in well-differentiated thyroid cancer (WDTC), sponsored by Eisai Co., Ltd.. Started Mar 2017; status: completed.
02
Drugs
lenvatinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20160121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160121.